|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Colestipol]] |
| {{colestipol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| ===WARNINGS===
| |
| | |
| TO AVOID ACCIDENTAL INHALATION OR ESOPHAGEAL DISTRESS, COLESTID GRANULES AND FLAVORED COLESTID GRANULES SHOULD NOT BE TAKEN IN ITS DRY FORM. ALWAYS MIX COLESTID AND FLAVORED COLESTID WITH WATER OR OTHER FLUIDS BEFORE INGESTING.
| |
| | |
| PHENYLKETONURICS: FLAVORED COLESTID CONTAINS 18.2 MG PHENYLALANINE PER 7.5-GRAM DOSE.
| |
| | |
| ===PRECAUTIONS===
| |
| | |
| Prior to initiating therapy with COLESTID Granules and FLAVORED COLESTID Granules, secondary causes of [[hypercholesterolemia ]](e.g., poorly controlled [[diabetes mellitus]], [[hypothyroidism]], [[nephrotic syndrome]], [[dysproteinemias]], obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation:
| |
| | |
| LDL-C = Total cholesterol - [ (Triglycerides / 5)+HDL-C]
| |
| | |
| For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In [[hypertriglyceridemic]] patients, LDL-C may be low or normal despite elevated Total-C. In such cases COLESTID and FLAVORED COLESTID may not be indicated.
| |
| | |
| Because it sequesters bile acids, colestipol hydrochloride may interfere with normal fat absorption and thus may reduce absorption of folic acid and fat soluble vitamins such as A, D, and K.
| |
| | |
| Chronic use of colestipol hydrochloride may be associated with an increased bleeding tendency due to [[hypoprothrombinemia]] from vitamin K deficiency. This will usually respond promptly to parenteral vitamin K1 and recurrences can be prevented by oral administration of vitamin K1.
| |
| | |
| Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm a favorable initial and adequate long-term response.
| |
| | |
| COLESTID and FLAVORED COLESTID may produce or severely worsen pre-existing [[constipation]]. The dosage should be increased gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-existing [[constipation]], the starting dose should be 1 packet or 1 scoop once daily for 5–7 days, increasing to twice daily with monitoring of [[constipation]] and of serum lipoproteins, at least twice, 4–6 weeks apart. Increased fluid and fiber intake should be encouraged to alleviate [[constipation]] and a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased as needed by one dose/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If [[constipation]] worsens or the desired therapeutic response is not achieved at one to six doses/day, combination therapy or alternate therapy should be considered. Particular effort should be made to avoid [[constipation]] in patients with symptomatic coronary artery disease. [[constipation]] associated with COLESTID and FLAVORED COLESTID may aggravate hemorrhoids.
| |
| | |
| While there have been no reports of [[hypothyroidism]] induced in individuals with normal thyroid function, the theoretical possibility exists, particularly in patients with limited thyroid reserve.
| |
| | |
| Since colestipol hydrochloride is a chloride form of an anion exchange resin, there is a possibility that prolonged use may lead to the development of [[hyperchloremic]] acidosis.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COLESTID (COLESTIPOL HYDROCHLORIDE) GRANULE, FOR SUSPENSION FLAVORED COLESTID (COLESTIPOL HYDROCHLORIDE) GRANULE, FOR SUSPENSION [PHARMACIA AND UPJOHN COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21b37725-fc0c-4365-a7dc-1a473d42502d | publisher = | date = | accessdate = 11 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| {{Lipid modifying agents}}
| |
| | |
| [[Category:Bile acid sequestrants]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |